MARKET NEWS

 

Vaxart Announces Positive Top-line Phase 2 Clinical Study Data Demonstrating Safety & Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
Hepion Pharmaceuticals Announces Initiation of Phase 2b ASCEND-NASH Trial
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome)
FDA Grants Fast Track Designation for Longeveron’s Treatment for Hypoplastic Left Heart Syndrome in Infants
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination With a PD-1 Pathway Inhibitor
Outlook Therapeutics Re-Submits BLA for ONS-5010 as a Treatment for Wet AMD 

  FEATURED EDITORIAL

  COMPANY PROFILE

Lyophilization Technology, Inc. (LTI) is a Contract Development & Manufacturing Organization (CDMO) focused on all aspects of lyophilization for preparation of health care products. Clients leverage on our abilities for bringing new products to the clinic and implementing improvements for current products. Capitalize on over 25 years of excellence and our unparalleled capabilities in product development, process engineering, clinical manufacturing, and technical support. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Novo Nordisk to Acquire Forma Therapeutics & Expand Presence in Sickle Cell Disease & Rare Blood Disorders

Novo Nordisk to Acquire Forma Therapeutics & Expand Presence in Sickle Cell Disease & Rare Blood Disorders

Novo Nordisk and Forma Therapeutics, Holdings Inc. recently announced they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for….

Qureight Announces World’s First Digital Biomarker for Lung Fibrosis

Qureight Announces World’s First Digital Biomarker for Lung Fibrosis

For the first time, artificial intelligence (AI) using convolutional neural networks has been used to analyse trial data involving the lung disease idiopathic pulmonary fibrosis (IPF). The technology picked up….

Laverock Therapeutics Founded to Develop the Next Generation of Programmable Cell Therapies

Laverock Therapeutics Founded to Develop the Next Generation of Programmable Cell Therapies

Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a….

Aria Pharmaceuticals Advances Pipeline With Six Provisional US Patents Filed Across Three Diseases

Aria Pharmaceuticals Advances Pipeline With Six Provisional US Patents Filed Across Three Diseases

Aria Pharmaceuticals recently announced the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s latest whitepaper outlines the key parameters that drug developers should considering while evaluating oral delivery …

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our whitepaper and learn …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 14 – Excipients
September 21 – Gene Therapy